Loading…
← CockpitCompetitor Analysis › 000513.SZ Livzon Pharmaceutical Group, Inc. Class AOpen in the cockpit ↗

Livzon Pharmaceutical Group, Inc. Class A000513.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhuhai-based pharmaceutical group making generics, diagnostic reagents and biologic/vaccine products.

Momentum leader 95
Mkt cap
$3.76B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$48.2M
20-day average traded
Fwd P/E
16.9×
forward earnings
ROIC−WACC
+10.1 pp
WACC 5.0%
Hurdle
-12 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥31.99
1D+0.9%
1W+2.5%
1M+17.4%
3M+3.9%
6M+3.6%
YTD-7.2%
1Y-12.1%
ATR %3.0%
52w lowhigh15.5% off high

What Livzon Pharmaceutical does

Zhuhai-based pharmaceutical group making generics, diagnostic reagents and biologic/vaccine products.

Sells medicines and diagnostic kits to Chinese hospitals and labs, where government drug-purchasing rules press prices on older generics and test kits sell on lab volume. Joincare Pharmaceutical, a listed Chinese drug group, is the controlling shareholder. The same company also trades in Hong Kong as 1513.HK.

Products and services

  • Generic pharmaceuticals
  • In-vitro diagnostic reagents
  • Biologics/vaccines

Customers

  • Hospitals
  • Diagnostic labs

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Generics + diagnostics + biologics

What could go right

  • Diagnostics and biologics pipeline growth

What could go wrong

  • Centralized procurement price cuts

Moat: narrow (scale, regulatory licence). Broad, diversified drug and diagnostics portfolio built over decades.

Headquarters: Zhuhai, China · Employees: 8,878

Named competitors

Livzon Pharmaceutical at a glance

Size Livzon Pharmaceutical (000513.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.76B, the 641st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.99 on 18 Nov 2026.

Performance Over six months the shares gained 3.6%, against +1.6% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 19 in its peer set.

Growth Revenue fell 13.7% over the last twelve months (peer median +10.3%); the operating margin is 19.2% (peer median 15.7%).

Valuation It trades at 16.9× forward earnings against a peer median of 21.0× (5th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 10.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026000513.SZ 103Peer median 103
Six months, rebased to 100: Livzon Pharmaceutical against the median of its 20 peers (local-currency closes).

Livzon Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥10.2BCN¥11.9BCN¥11.7BCN¥12.3BCN¥12.5B
Revenue growth—+2%-5%-2%—
Gross profitCN¥6.62BCN¥7.63BCN¥7.45BCN¥7.40BCN¥7.75B
EBITDAn/aCN¥3.18BCN¥3.18BCN¥2.79BCN¥2.60B
Net incomeCN¥1.56BCN¥2.02BCN¥2.06BCN¥1.95BCN¥1.91B
Free cash flowCN¥2.77BCN¥2.60BCN¥2.42BCN¥2.57BCN¥1.96B
Capital expenditureCN¥412MCN¥574MCN¥570MCN¥820MCN¥940M
Total debtCN¥4.20BCN¥3.85BCN¥4.95BCN¥5.04BCN¥4.63B

Quarterly statements and history in the cockpit →

Livzon Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%600329ROVITARSXENE688336SLSOGN3320128940DFTXWOCKPHARMASFZNACUTAAS1877ARQT000513.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Livzon Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×60×600329ROVI688336OGN6005213320128940ACUTAASARQT000100000513.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Livzon Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%600329ROVITARS688336OGN301569ARQT000513.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Livzon Pharmaceutical is the large dot.

Livzon Pharmaceutical competitors and peer comparison

Head to head with its named competitors (000513.SZ vs 002294.SZ vs 600079.SS vs 000963.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Livzon Pharmaceutical 000513.SZ$3.76B+4%-14%19%16.9×-9.6%
Shenzhen Salubris Pharmaceuticals 002294.SZ$4.31B-24%+14%11%35.4×12.4%
Humanwell Healthcare (Group) 600079.SS$4.87B+11%+2%15%13.8×-8.8%
Huadong Medicine 000963.SZ$6.69B-18%+2%9%12.5×-3.9%
Shanghai Fosun Pharmaceutical (Group) 600196.SS$7.57B-14%+8%6%14.8×2.9%
Cspc Pharma 1093.HK$12.0B+10%+25%28%9.1×-10.7%
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%26.7×15.8%

How Livzon Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Livzon Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000513.SZPeer medianRank in peer set
1-month return+17.4%-0.2%3rd highest of 21
6-month return+3.6%+1.6%9th highest of 19
Distance from 52-week high-15.5%-29.5%5th highest of 21
Revenue growth (TTM)-13.7%+10.3%2nd lowest of 18
Operating margin19.2%15.7%7th highest of 17
Forward P/E16.9×21.0×5th cheapest of 13
Growth the price implies (Req g, 7 yrs)-9.6%5.5%least demanding of 13
Growth delivered (Del g)+2.7%+7.7%3rd lowest of 13
Hurdle (Req g minus delivered)-12.3 pp-7.0 pp6th least demanding of 13
ROIC minus cost of capital+10.1 pp+4.3 pp5th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a

Questions

Who are Livzon Pharmaceutical's main competitors?
Named competitors: Shenzhen Salubris Pharmaceuticals (002294.SZ), Humanwell Healthcare (600079.SS), Huadong Medicine (000963.SZ), Shanghai Fosun Pharmaceutical (600196.SS), CSPC Pharmaceutical (1093.HK), Hualan Biological Engineering (002007.SZ). The cockpit's measured peer set (industry) also includes Tianjin Pharmaceutical Da Ren Tang (600329.SS), Laboratorios Farmaceuticos Rovi (ROVI.MC), Tarsus Pharmaceuticals (TARS), Xenon Pharmaceuticals (XENE), Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS), SELLAS Life Sciences (SLS).
Is Livzon Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.9× against a peer median of 21.0×, 5th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Livzon Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +3.6% against +1.6% for the median peer; over one year -12.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.